Add BrightSurf on Google Email

How to achieve a functional cure for chronic hepatitis B

Researchers found that after 96 weeks, some patients achieved loss of detectable HBsAg and reduced liver inflammation levels, indicating functional cure. The study suggests that discontinuing long-term antiviral therapy may be more effective than continuing it for certain patients.

SourceElsevier·JournalJournal of Hepatology·TypeRandomized controlled/clinical trial·DateMar 30, 2023

How to achieve a functional cure for chronic hepatitis B

A study published in Journal of Hepatology found that some patients with chronic hepatitis B can achieve sustained immune control by discontinuing antiviral therapy after four years. This suggests a potential cure for the disease, which affects an estimated 350 million people worldwide.

SourceUniversität Leipzig·JournalJournal of Hepatology·TypeRandomized controlled/clinical trial·DateMar 30, 2023

New method for producing synthetic DNA

The new method streamlines DNA production by automating the synthesis of phosphoramidites, eliminating manual labor and storage issues. This breakthrough has significant implications for disease identification, drug manufacturing, and other medical applications.

SourceAarhus University·JournalNature Communications·DateMay 12, 2021

First patient affected by a mutation in the nucleoside transporter SLC28 gene family

Researchers have identified a mutation in the SLC28A1 gene, affecting the synthesis of the hCNT1 protein and altering pyrimidine metabolism. The study provides insights into the potential role of nucleoside transporters in regulating cellular processes and may lead to new therapeutic approaches for cancer treatment.

SourceUniversity of Barcelona·JournalBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease·DateFeb 5, 2019

Cracking the mystery of Zika virus replication

Researchers from Tianjin University and Nankai University have unraveled the puzzle of how Zika virus replicates. They discovered a tunnel in the enzyme that holds viral RNA, allowing it to unwind its genetic material. This breakthrough could lead to the development of antiretroviral drugs against this spreading disease.

SourceSpringer·JournalProtein & Cell·DateJul 26, 2016

Two studies compare triple nucleoside therapy Ziagen® + Combivir® with protease inhibitorplus Combivir® regimens in therapy-naive patients

Two studies compare the efficacy and adherence of the triple nucleoside regimen of Ziagen/Combivir versus PI-containing regimens. Preliminary data show that patients on the Ziagen/Combivir regimen had better viral load suppression, with 68% achieving <400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen.